PharmiWeb.com - Global Pharma News & Resources

Press Releases

Date Title Company
23-Oct-2024 CluePoints Wins Growth Award at BVA Private Equity Awards CluePoints
23-Oct-2024 Primum Appoints Erica Conroy as CEO, Strengthening Ohio’s Role in Revolutionizing Cancer Care AccessWire
23-Oct-2024 Ten businesses embark on Discovery Park’s ‘Discovery Spark’ programme Discovery Park
23-Oct-2024 Watson-Marlow Fluid Technology Solutions to showcase peristaltic filling machines and new single-use solutions at PACK EXPO International 2024 Watson-Marlow Fluid Technology Group
23-Oct-2024 Nitches, Inc. Unveils InTheZone Focused Extreme: A Premium Supplement for Enhanced Focus and Cognitive Performance Newswire
23-Oct-2024 New genetic screening programme should be extended to test for untreatable conditions, says leading biotech Innovate UK
23-Oct-2024 New genetic screening programme should be extended to test for untreatable conditions, says leading biotech SynaptixBio
23-Oct-2024 ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares ProQR Therapeutics
23-Oct-2024 ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement ProQR Therapeutics N.V.
23-Oct-2024 ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement ProQR Therapeutics
23-Oct-2024 4Tissue Raises €2M to Advance Groundbreaking Breast Tissue Replacement Technology 4Tissue
23-Oct-2024 Capital Markets Event 2024: Lundbeck to showcase progress on Focused Innovator Strategy driving sustainable long-term growth H. Lundbeck A/S
23-Oct-2024 DARZALEX® (daratumumab)-SC based quadruplet regimen approved by the European Commission for patients with newly diagnosed multiple myeloma who are transplant-eligible Janssen-Cilag International NV
23-Oct-2024 Senzime secures first European hospital order for its new next-generation TetraGraph system Senzime
23-Oct-2024 Biocartis announces six Idylla™ abstracts to be presented at AMP 2024 Annual Meeting Biocartis NV
23-Oct-2024 ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement ProQR Therapeutics
23-Oct-2024 Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset Angelini Pharma
23-Oct-2024 LILLY RECEIVES MHRA MARKETING AUTHORISATION IN GREAT BRITAIN FOR DONANEMAB (KISUNLA ®▼) FOR THE TREATMENT OF MILD COGNITIVE IMPAIRMENT AND MILD DEMENTIA DUE TO ALZHEIMER’S DISEASE IN ADULT PATIENTS WHO ARE APOLIPOPROTEIN E ε4 HETEROZYGOTES OR NON-CARRIERS Eli Lilly and Company Limited
23-Oct-2024 OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain OKYO Pharma Limited
23-Oct-2024 ZetrOZ Systems and TOBI Network Announce Webinar on Sustained Acoustic Medicine for Discogenic Back Pain AccessWire